Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.71 |
| ▸ | FYN | P06241 | 14/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040054 | 0.90 | MKNK1 (0.69) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3033275 | 0.85 | MKNK1 (0.76) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3031531 | 0.83 | MKNK1 (0.69) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3031885 | 0.83 | MKNK1 (1.00) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3037232 | 0.83 | MKNK1 (0.62) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3033429 | 0.82 | MKNK1 (1.00) | MKNK1FYNKCNH2 | |
| SCHEMBL3036473 | 0.81 | MKNK1 (0.81) | MKNK1FYNKCNH2DYRK3CCNT1 | |
| SCHEMBL3036694 | 0.78 | MKNK1 (0.73) | MKNK1FYNKCNH2NTRK1NTRK3 | |
| SCHEMBL3042012 | 0.77 | MKNK1 (0.85) | MKNK1FYNKCNH2 | |
| SCHEMBL18613425 | 0.77 | FYN (1.00) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | MKNK1 816/4885FYN 3/4885KCNH2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.